Objective: To investigate the expressions of BRAF V600E, CK19 and galectin-3 antibodies in papillary thyroid carcinoma, and study the diagnostic value of BRAF V600E antibody when in corporating with the clinicopathological characteristics of PTC. Methods: The clinicopathological data of 80 patients with PTC were analyzed; 31 cases of nodular goiter and 13 cases with Hashimoto thyroiditis were served as controls. BRAF V600E, CK19 and galectin-3 antibodies in PTC and control group were detecteds and the correlation between BRAF V600E antibody and clinicopathological characteristics of PTC was analyzed. Results: Correlation between thyroid membrane invasion and lymph node metastasis was observed in PTC patients(P<0.05). The positive rates of BRAF V600E, CK19 and galectin-3 antibodies in patients with PTC were 62.50%, 98.75%, 95.00%, respectively. The sensitivity of CK19 combined with galectin-3antibodies was 95.00%, and the specificity of BRAF V600 antibody was 100%. The specificity of CK19 and galection-3 antibodies could be improved by combining with BRAF V600 antibody. There was no statistical correlation between expression of BRAF V600E antibody and age, gender, lesion size, thyroid membrane invasion, lymph node metastasis, histological subtype of PTC (P>0.05). Conclusions: The combined detection of BRAF V600E, CK19 and Galectin-3 antibodies is helpful for the pathological diagnosis of PTC.Meanwhile, BRAF V600E antibody plays a preliminary screening role for the mutation of BRAF V600E gene.
CAI Rong, MIN Xuewen, CHEN Meirong, SHEN Yating, SHI Qunli, ZHOU Xiaodie
. Expression of BRAF V600E (VE1) in thyroid papillary carcinoma and its clinical significance[J]. Journal of Diagnostics Concepts & Practice, 2018
, 17(05)
: 552
-556
.
DOI: 10.16150/j.1671-2870.2018.05.013
[1] Jemal A, Bray F, Center MM, et al.Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69-90.
[2] Tuttle RM, Ball DW, Byrd D, et al.Thyroid carcinoma[J]. J Natl Compr Canc Netw,2010,8(11):1228-1274.
[3] Kim SK, Song KH, Lim SD, et al.Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis[J]. Thyroid,2009,19(2):137-141.
[4] 滕晓东, 王丽君, 姚洪田, 等. 细胞角蛋白19、galectin-3、HBME-1在甲状腺病变上的表达及鉴别诊断意义[J]. 中华病理学杂志,2004,33(3):212-216.
[5] 陈云新, 沈丹华, 孙昆昆, 等. 甲状腺微小乳头状癌中Galectin-3、CK19、HBME-1和CD56的表达及意义[J]. 临床与实验病理学杂志,2010,26(4):425-428.
[6] 佟杰, 王岩, 笪冀平. CK19HBME-1Galectin-3等表达在甲状腺乳头状微小癌与良性病变鉴别诊断中的意义[J]. 中华肿瘤杂志,2011,33(8):599-604.
[7] 郑璐滢, 朱建善, 王家东, 等. Galectin-3、CK19和TPO表达在甲状腺良恶性肿瘤病理诊断中的价值[J]. 临床与实验病理学杂志,2005,20(4):449-452.
[8] 邓敏, 叶顾萍, 马建中, 等. 甲状腺乳头状癌中CK19、Galectin-3、HBME-1和TPO的表达及意义[J]. 临床与实验病理学杂志,2011,27(8):843-846.
[9] 白杨, 孙璐, 郭爱桃, 等. CK19、galectin-3和syndecan-1在甲状腺乳头状病变鉴别诊断中的意义[J]. 诊断病理学杂志,2013,20(12):771-774.
[10] 怀建国, 蒋艳, 杨小苗, 等. 免疫组化联合检测在甲状腺乳头状病变诊断中的意义[J]. 诊断病理学杂志,2015,22(7):433-435.
[11] Kim TY, Kim WB, Rhee YS, et al.The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf),2006,65(3):364-368.
[12] Yip L, Nikiforova MN, Carty SE, et al.Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation[J]. Surgery,2009,146(6):1215-1223.
[13] Xing M, Alzahrani AS, Carson KA, et al.Association between BRAF V600E mutation and recurrence of papillary thyroid cancer[J]. J Clin Oncol,2015,33(1):42-50.
[14] Prescott JD, Sadow PM, Hodin RA, et al.BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence[J]. Surgery,2012,152(6):984-990.
[15] Abd Elmageed ZY, Sholl AB, Tsumagari K, et al.Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer[J]. Surgery,2017,161(4):1122-1128.
[16] 陈公仆, 王圣应, 郑绪才. 超声引导下细针穿刺细胞学检查对鉴别甲状腺良恶性肿瘤的价值[J]. 安徽医学,2017,38(12):1570-1571.
